<DOC>
	<DOCNO>NCT02559310</DOCNO>
	<brief_summary>This study evaluate safety efficacy lefamulin , pleuromutilin , treatment adult moderate severe community-acquired bacterial pneumonia .</brief_summary>
	<brief_title>Study Compare Lefamulin Moxifloxacin ( With Without Linezolid ) Treatment Adults With Pneumonia</brief_title>
	<detailed_description>Lefamulin potent , semi-synthetic antibacterial belonging novel class know pleuromutilins . Both intravenous ( IV ) oral dosage form lefamulin investigation study . Lefamulin 's vitro antibacterial profile include important bacterial pathogen cause respiratory tract infection ( RTI ) . The antibacterial spectrum comprises S. pneumoniae , H. influenzae , M. catarrhalis , atypical respiratory pathogen L. pneumophila , C. pneumoniae , M. pneumoniae , S. aureus include MRSA CA-MRSA , ß-haemolytic streptococci include S. pyogenes S. agalactiae , Enterococcus faecium include vancomycin-resistant enterococci ( VRE ) . Moreover , demonstrate cross-resistance study , lefamulin remain active clinical isolates resistant follow antimicrobial ( ) ( class ) : macrolides , lincosamides , streptogramin B , oxazolidinones , tetracycline , ß lactams , quinolones , trimethoprim-sulfametoxazole , mupirocin , vancomycin .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Be male female least 18 year age . 2 . Provide write informed consent willing able adhere studyspecified procedure restriction . 3 . Have acute illness ( 7 day duration ) least 3 follow symptom consistent low respiratory tract infection ( new worsen ) : Dyspnea New increase cough Purulent sputum production Chest pain due pneumonia 4 . Have least 2 follow vital sign abnormality : Fever ( body temperature &gt; 38.0°C ( 100.4°F ) measure orally equivalent temperature alternate body site ) hypothermia ( body temperature &lt; 35.0°C ( 95.0°F ) measure orally equivalent temperature alternate body site ) Hypotension ( systolic blood pressure &lt; 90 mmHg ) Tachycardia ( heart rate &gt; 100 beats/min ) Tachypnea ( respiratory rate &gt; 20 breaths/min ) 5 . Have least 1 clinical sign laboratory find CABP : Hypoxemia ( i.e. , O2 saturation &lt; 90 % room air receive supplemental oxygen subject 's baseline requirement PaO2 &lt; 60 mmHg ) Auscultatory and/or percussion finding consistent pneumonia ( e.g. , crackle , egophony , dullness ) White blood cell ( WBC ) count &gt; 10,000 cells/mm3 &lt; 4500 cells/mm3 &gt; 15 % immature neutrophil ( band ) regardless total WBC count 6 . Have radiographicallydocumented pneumonia within 48 hour enrollment ( i.e. , infiltrate lobar multilobar distribution diffuse opacities chest xray chest compute tomography scan consistent acute bacterial pneumonia ) . 7 . Have Pneumonia Outcomes Research Team ( PORT ) Risk Class ≥III . 1 . Have receive single dose shortacting oral IV antibacterial CABP within 72 hour randomization 2 . Require concomitant systemic antibacterial therapy potentially effective CABP pathogens 3 . Have hospitalize 2 day within 90 day prior onset symptom reside nursing home longterm healthcare facility within 30 day prior onset symptom . NOTE : Residence independent living facility permit . 4 . Have confirm suspect CABP cause pathogen know resistant study drug ( e.g. , Pseudomonas aeruginosa , pathogen Enterobacteriaceae Family ) attributable etiology community acquire bacterial pathogen ( e.g. , ventilator associate pneumonia , hospital acquire bacterial pneumonia , bacterial aspiration pneumonia , Pneumocystis jiroveci pneumonia fungal pneumonia , viral mycobacterial infection lung ) . 5 . Have noninfectious cause pulmonary infiltrates ( e.g. , pulmonary embolism , chemical pneumonitis aspiration , hypersensitivity pneumonia , congestive heart failure , bronchial obstruction , lung cancer , cystic fibrosis ) . 6 . Have confirm suspected pleural empyema ( include sterile parapneumonic effusion ) . 7 . Require mechanical ventilation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pneumonia</keyword>
	<keyword>CABP</keyword>
	<keyword>CAP</keyword>
	<keyword>Community acquire bacterial pneumonia</keyword>
</DOC>